Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
23 mars 2023 13h23 HE
|
Avalyn Pharma Inc.
SEATTLE , March 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for life-threatening pulmonary diseases,...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
21 févr. 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February 2023. Kinarus Therapeutics...
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
17 janv. 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...
Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
10 janv. 2023 09h00 HE
|
InSilico Medicine
New York, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of...
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
06 déc. 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report...
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
05 déc. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
22 nov. 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics...
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
16 nov. 2022 01h00 HE
|
Kinarus Therapeutic Holding AG
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunitiesMultiple opportunities for KIN001 in indications with high unmet need are...
Kinarus Therapeutics Provides Strategic Update
04 nov. 2022 02h00 HE
|
Kinarus Therapeutic Holding AG
Exploring financial and strategic options to fund Phase 2 trials of KIN001 in wet age-related macular degeneration and idiopathic pulmonary fibrosisKINFAST phase 2 clinical trial of KIN001 in mild to...
FibroGen to Participate at Stifel 2022 Healthcare Conference
01 nov. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...